Girentuximab
| Drug Information | |||
|---|---|---|---|
| Image | |||
| Identifiers
CAS Number ATC Code PubChem DrugBank ChemSpider ID UNII KEGG ChEBI ChEMBL IUPAC Name |
Chemical Data
C H N O Molecular Weight | ||
Girentuximab is a monoclonal antibody designed for the treatment of renal cell carcinoma (RCC). It specifically targets carbonic anhydrase IX (CAIX), a protein that is highly expressed in several types of cancer, including RCC, but has limited expression in normal tissues. Girentuximab is currently under clinical development and has not yet been approved for clinical use.
Mechanism of Action[edit | edit source]
Girentuximab binds to the CAIX antigen on the surface of tumor cells. CAIX is involved in pH regulation and cell survival in hypoxic environments typical of solid tumors. By targeting CAIX, girentuximab may inhibit tumor growth and survival. The antibody is labeled with radioactive isotopes in some formulations, allowing it to deliver targeted radiation to the tumor cells, a therapy known as radioimmunotherapy.
Clinical Trials[edit | edit source]
Girentuximab has been evaluated in several clinical trials, primarily focusing on its safety and efficacy in patients with advanced renal cell carcinoma. Early trials have shown promise in terms of specificity and targeting capability, but further studies are required to fully assess its therapeutic potential and safety profile.
Development and Regulatory Status[edit | edit source]
As of the last update, girentuximab is in the phase III of clinical trials. The drug is being developed by a biopharmaceutical company specializing in cancer therapies. It has been granted orphan drug status in the United States and Europe, which may facilitate its development and potential approval process due to the benefits such status confers.
Potential Side Effects[edit | edit source]
As with any cancer therapy, girentuximab may cause side effects. The specific side effects related to its use are not fully known due to its investigational status. However, potential side effects could relate to its mechanism of action and the general effects of monoclonal antibodies, including infusion reactions and effects from targeted radiation.
Future Directions[edit | edit source]
Research continues to focus on optimizing the dosing and administration of girentuximab, as well as expanding its potential indications. Studies are also exploring the combination of girentuximab with other therapeutic agents to enhance its efficacy and reduce potential resistance.
See Also[edit | edit source]
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
